311 related articles for article (PubMed ID: 26142691)
1. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
Yoo I; Woo JM; Lee SH; Fava M; Mischoulon D; Papakostas GI; Kim EJ; Chung S; Ha JH; Jeon HJ
J Affect Disord; 2015 Oct; 185():24-30. PubMed ID: 26142691
[TBL] [Abstract][Full Text] [Related]
2. Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: a 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
Jeon HJ; Woo JM; Lee SH; Kim EJ; Chung S; Ha JH; Fava M; Mischoulon D; Kim JH; Heo JY; Yu BH
J Clin Psychopharmacol; 2014 Apr; 34(2):218-25. PubMed ID: 24525660
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study.
Emsley R; Ahokas A; Suarez A; Marinescu D; Dóci I; Lehtmets A; Milanova V; Lee MS; Didi R; Araszkiewicz A; Sulaiman AH; Blanchot FP; Crutel VS; Antoine C; Penelaud PF
J Clin Psychiatry; 2018 Jul; 79(4):. PubMed ID: 29995359
[TBL] [Abstract][Full Text] [Related]
4. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
6. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
Demyttenaere K; Andersen HF; Reines EH
Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.
Mohamed S; Osatuke K; Aslam M; Kasckow J
Am J Geriatr Pharmacother; 2006 Sep; 4(3):201-9. PubMed ID: 17062320
[TBL] [Abstract][Full Text] [Related]
8. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
12. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.
Maity N; Ghosal MK; Gupta A; Sil A; Chakraborty S; Chatterjee S
Indian J Pharmacol; 2014; 46(4):433-7. PubMed ID: 25097285
[TBL] [Abstract][Full Text] [Related]
14. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
15. Verbal memory predicts treatment outcome in syndromal anxious depression: An iSPOT-D report.
Braund TA; Tillman G; Palmer DM; Harris AWF
J Affect Disord; 2020 Jan; 260():245-253. PubMed ID: 31513968
[TBL] [Abstract][Full Text] [Related]
16. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial.
Soczynska JK; Ravindran LN; Styra R; McIntyre RS; Cyriac A; Manierka MS; Kennedy SH
Psychiatry Res; 2014 Dec; 220(1-2):245-50. PubMed ID: 25124683
[TBL] [Abstract][Full Text] [Related]
17. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
Olié JP; Tonnoir B; Ménard F; Galinowski A
Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
Brown ES; Howard C; Khan DA; Carmody TJ
Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
[TBL] [Abstract][Full Text] [Related]
20. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
